Sneed Jr. v. AcelRx Pharmaceuticals, Inc.
Opinion
Trial Court Opinion
UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA SAN JOSE DIVISION 6 AARON SNEED JR., Case No. 21-cv-04353-BLF
Plaintiff,
ORDER GRANTING MOTION TO
v. DISMISS SECOND AMENDED
COMPLAINT WITH LEAVE TO
ACELRX PHARMACEUTICALS, INC., et AMEND IN PART AND WITHOUT al., LEAVE TO AMEND IN PART 11 Defendants. [Re: ECF No. 78] 12 Now before the Court is Defendants’ motion to dismiss the Second Amended Complaint in this putative securities class action. ECF No. 78 (“MTD”); see also ECF No. 83 (“Reply”). Plaintiffs oppose the motion. ECF No. 82 (“Opp.”). For the reasons discussed at the May 30, 2023 motion hearing and further explained below, the Court GRANTS Defendants’ motion to dismiss WITH LEAVE TO AMEND IN PART and WITHOUT LEAVE TO AMEND IN PART. I. BACKGROUND On June 8, 2021, Plaintiff Aaron Sneed Jr. filed a securities class action suit in this Court alleging violations of various securities laws by AcelRx Pharmaceuticals,…